FDA approves Merck’s Lipfendra, the first cholesterol-lowering pill in a drug class dominated by injections, cutting LDL nearly 60% in trials.
$315 monthly, available within weeks
Read the full story at USA Today
From the July 16, 2026 GovBrief, every story that day in one place.